$RKLB

Key facts: Rocket Lab (RKLB) Q2 strong; targets raised; Neutron Q4 2026

Rocket Lab (RKLB) reported Q2 revenue of about $234.1M, up 62% YoY, with a GAAP loss of $0.08 per share. The company said it has a record $2.36B backlog, about $2.2B cash, and non-GAAP gross margin of 41.5%. It raised Neutron delivery timing to Q4 2026 and analysts at Cantor Fitzgerald and Citizens lifted price targets to $122 and $130.

Original reporting
Published Aug 12, 2026, 7:14 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: Rocket Lab (RKLB) Q2 strong; targets raised; Neutron Q4 2026 — source image
Decision brief

The 30-second read

$RKLBBullishMed
01

Why it matters

Q2 strength (revenue growth, record backlog, gross margin) plus additional launch deals can improve near-term visibility, while Neutron timing uncertainty can keep valuation sensitive to execution risk.

02

Market read

Fresh Q2 metrics and a Neutron delivery schedule update provide a concrete catalyst for RKLB positioning, tempered by CEO commentary on potential slippage.

03

What to watch

The summary cites a GAAP loss and after-hours share drop; traders may focus on cash burn trajectory and execution milestones rather than backlog alone.

Relevance 7/10Novelty 6/10Timing: after-hours context, pre-decision for next-session positioning

Background

The piece is a brief recap of Rocket Lab’s Q2 performance and an update to Neutron rocket delivery timing, alongside analyst target changes.

Company-level read

Ticker impact

$RKLBBullishMedium confidence
Context

Rocket Lab reports Q2 revenue of about $234.1M, record backlog $2.36B, and raises Neutron delivery timing to Q4 2026.

Expected impact

Near-term upside bias with volatility, as timing uncertainty offsets the stronger backlog and margin metrics.

Evidence & confidence

The article contains multiple fresh, company-specific datapoints (Q2 results, backlog/cash, new launch deals, and Neutron delivery window) plus a CEO timing caveat that can temper the market reaction.

Market effects

Signals continued demand and execution progress in commercial launch, potentially supporting sentiment across small/mid-cap space names.

Limited direct regional read-through; primarily US-listed small-cap space sentiment.

Moderate, as Neutron schedule updates can influence global launch competition expectations.

Counterpoint

Neutron schedule uncertainty (maiden flight could slip past 2026) may mean today’s raised delivery window is still not de-risked enough to sustain a rerating.

Key entities

  • Rocket Lab

    Reports Q2 results and updates Neutron delivery timing to Q4 2026, with CEO noting maiden flight could slip past 2026.

  • Cantor Fitzgerald

    Raised its price target to $122 citing Neutron progress.

  • Citizens

    Maintained/kept a $130 target after the results.

Related articles

$RKLBMed

Neutron Launch Chances This Year Narrowing, Rocket Lab Says

Rocket Lab said the launch window for its Neutron test flight this year is narrowing, with CEO Peter Beck reiterating the company remains committed to completing the Wallops Island, Virginia launchpad by year end. The prior forecast was Oct-Dec after a Stage 1 tank fault. Rocket Lab reported Q2 2026 sales of $234M and narrowed net loss to $49.3M, alongside $437M in bookings.

$ASTSMed

ASTS Vs RKLB: The Market Picked One, Cathie Wood Backed The Other — Which Space Play Won Q2?

Rocket Lab (RKLB) shares fell slightly after Q2 results that included record revenue of $234.07 million, up 62% year over year, and a wider-than-expected loss of $0.08 per share. It guided Q3 revenue to $250 million-$265 million. AST SpaceMobile (ASTS) rose 4% on its results, but reported $31.5 million revenue and a $0.77 loss per share. Analysts cut ASTS targets while raising RKLB targets; ARK bought $23.43 million of RKLB shares.

$RKLBMed

Rocket Lab just put its biggest 2026 milestone at risk

Rocket Lab (RKLB) reported Q2 revenue of $234 million, up 62% year over year, with its space-systems unit generating 81% of sales. Despite beating Wall Street expectations, shares fell about 7% in extended trading. Reuters said Rocket Lab now expects Neutron’s first-stage tank to reach the launch pad in Q4 2026, with a “hopefully” launch window narrowing.

$RKLBMed

Rocket Lab’s GHOST Ships Orbital Launch Pads Worldwide; Licenses Cannot Follow

Rocket Lab said on Aug. 10, 2026 that it will offer GHOST, a containerized orbital launch pad system that can be shipped and deployed worldwide. The company unveiled it during its Q2 2026 earnings call, alongside $234 million quarterly revenue. First deployment is planned for Launch Complex 4 at Kodiak, Alaska, with operations starting in 2027, subject to licensing and safety requirements.

$RKLBMedAI 8/10

RKLB Q2 Deep Dive: Iridium Acquisition, Neutron Progress, and Margin Pressures Shape Outlook

Rocket Lab (NASDAQ:RKLB) reported Q2 CY2026 revenue of $234.1 million, up 62% year on year, and guided next-quarter revenue to $257.5 million at the midpoint. Management cited strong satellite contract wins and Neutron progress, while attributing margin pressure to Mynaric integration costs. The company also plans to acquire Iridium and expects cash outflows to remain elevated until Neutron’s first test flight.

$RKLBMed

Rocket Lab Falls 7% as Neutron Launch Window Narrows

Rocket Lab Corp. (RKLB) fell about 7% in extended trading after management said the first Neutron rocket flight may slip beyond 2026. The company now targets Neutron to reach the launch pad in Q4, with a year-end window narrowing. It expects Q3 gross margin of 29% to 31% versus a 37.6% estimate, despite Q2 revenue rising 62% to $234 million.

Key facts: Rocket Lab (RKLB) Q2 strong; targets raised; Neutron Q4 2026 — alphai